{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:49:43Z","timestamp":1781560183050,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40261-022-01173-3","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T12:05:56Z","timestamp":1657627556000},"page":"643-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-1867","authenticated-orcid":false,"given":"Daniel Tobias","family":"Michaeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-7161","authenticated-orcid":false,"given":"Julia Caroline","family":"Michaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-4180","authenticated-orcid":false,"given":"Tobias","family":"Boch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-9401","authenticated-orcid":false,"given":"Thomas","family":"Michaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"1173_CR1","unstructured":"Office for National Statistics. Leading causes of death, UK: 2001 to 2018. Registered leading causes of death by age, sex and country. 2020. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/causesofdeath\/articles\/Leadingcausesofdeathuk\/2001to2018. Accessed 16 Jan 2022."},{"key":"1173_CR2","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337.","journal-title":"Eur Heart J"},{"key":"1173_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350\u20137.","journal-title":"JAMA"},{"key":"1173_CR4","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556\u201364.","journal-title":"JAMA"},{"key":"1173_CR5","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"1173_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"1173_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1173_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322.","journal-title":"N Engl J Med"},{"key":"1173_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203\u201312.","journal-title":"N Engl J Med"},{"key":"1173_CR10","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med"},{"key":"1173_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1173_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372.","journal-title":"N Engl J Med"},{"key":"1173_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/CIRCOUTCOMES.115.002104","volume":"9","author":"R Klempfner","year":"2016","unstructured":"Klempfner R, Erez A, Sagit B-Z, Goldenberg I, Fisman E, Kopel E, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes. 2016;9:100\u20138.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1173_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229\u201343.","journal-title":"Circ Res"},{"key":"1173_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/eurheartj\/ehz859","volume":"41","author":"A Timmis","year":"2020","unstructured":"Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41:12\u201385.","journal-title":"Eur Heart J"},{"key":"1173_CR16","doi-asserted-by":"crossref","unstructured":"Ademi Z, Ofori-Asenso R, Zomer E, Owen A, Liew D. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction: Eur J Prev Cardiol. 2021;28(8):897\u2013904.","DOI":"10.1177\/2047487319896648"},{"key":"1173_CR17","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0735-1097(20)32541-9","volume":"75","author":"WS Weintraub","year":"2020","unstructured":"Weintraub WS, Bhatt, Zugui Z, Cheng Z, Dolman S, Boden WE, et al. Cost-effectiveness of icosapent ethyl in us reduce-it patients. J Am Coll Cardiol. 2020;75:1914\u20131914.","journal-title":"J Am Coll Cardiol"},{"key":"1173_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejim.2019.07.001","volume":"67","author":"L Gao","year":"2019","unstructured":"Gao L, Moodie M, Li S-C. The cost-effectiveness of omega-3 polyunsaturated fatty acids\u2014the Australian healthcare perspective. Eur J Intern Med. 2019;67:70\u20136.","journal-title":"Eur J Intern Med"},{"key":"1173_CR19","unstructured":"Ollendorf DA, McQueen RB, Campbell JD, Synnott PG, Herron-Smith S, Fazioli K, et al. Additive therapies for cardiovascular disease: effectiveness and value. Institute for Clinical and Economic Review; 2019. Available from: https:\/\/icer.org\/assessment\/cvd-additive-therapies-2019\/. Accessed 22 Mar 2022."},{"key":"1173_CR20","doi-asserted-by":"publisher","first-page":"S496","DOI":"10.1016\/j.jval.2020.08.546","volume":"23","author":"J Lachaine","year":"2020","unstructured":"Lachaine J, Charron JN, Gregoire JC, Hegele RA, Leiter LA. PCV55 cost-effectiveness of icosapent ethyl (IPE) for the reduction of the risk of ischemic cardiovascular events in Canada. Value Health. 2020;23:S496.","journal-title":"Value Health."},{"key":"1173_CR21","unstructured":"CADTH Canadian Drug Expert Committee Recommendation: Icosapent Ethyl (Vascepa\u2014HLS Therapeutics Inc.): Indication: prevention of cardiovascular events in statin-treated patients. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566005\/. Accessed 23 Jan 2022."},{"key":"1173_CR22","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamacardio.2019.1647","volume":"4","author":"GC Fonarow","year":"2019","unstructured":"Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P. Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4:691\u20135.","journal-title":"JAMA Cardiol."},{"key":"1173_CR23","doi-asserted-by":"publisher","unstructured":"Michaeli DT, Michaeli JC, Boch T, Michaeli T. Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany. Cardiovasc Drugs Ther. 2022. https:\/\/doi.org\/10.1007\/s10557-021-07310-y.","DOI":"10.1007\/s10557-021-07310-y"},{"key":"1173_CR24","unstructured":"National Institute for Health and Care Excellence (NICE). Developing NICE guidelines: the manual\u2014process and methods [PMG20]. 2020. Available from: https:\/\/www.nice.org.uk\/process\/pmg20\/resources. Accessed 15 Jan 2022."},{"key":"1173_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40273-020-00936-0","volume":"38","author":"C Marquina","year":"2020","unstructured":"Marquina C, Zomer E, Vargas-Torres S, Zoungas S, Ofori-Asenso R, Liew D, et al. Novel treatment strategies for secondary prevention of cardiovascular disease: a systematic review of cost-effectiveness. Pharmacoeconomics. 2020;38:1095\u2013113.","journal-title":"Pharmacoeconomics"},{"key":"1173_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011805","volume":"6","author":"MD Danese","year":"2016","unstructured":"Danese MD, Gleeson M, Kutikova L, Griffiths RI, Azough A, Khunti K, et al. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. 2016;6: e011805.","journal-title":"BMJ Open"},{"key":"1173_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/dme.12647","volume":"32","author":"ML Alva","year":"2015","unstructured":"Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med J Br Diabet Assoc. 2015;32:459\u201366.","journal-title":"Diabet Med J Br Diabet Assoc."},{"key":"1173_CR28","doi-asserted-by":"crossref","unstructured":"Reifsnider OS, Kansal AR, Franke J, Lee J, George JT, Brueckmann M, et al. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC Heart Fail. 2020;7(6):3910\u20133918.","DOI":"10.1002\/ehf2.12985"},{"key":"1173_CR29","unstructured":"T. Georghiou, M. Bardsley. Exploring the cost of care at the end of life. London: Nuffield Trust Research Report. 2014. Available from: https:\/\/www.nuffieldtrust.org.uk\/files\/2017-01\/end-of-life-care-web-final.pdf. Accessed 5 Jul 2022."},{"key":"1173_CR30","unstructured":"Public Health England. Statistical commentary: End of life care profiles, February 2018 update. 2018. Available from: https:\/\/www.gov.uk\/government\/statistics\/end-of-life-care-profiles-february-2018-update\/statistical-commentary-end-of-life-care-profiles-february-2018-update. Accessed 16 Jan 2022."},{"key":"1173_CR31","volume-title":"British national formulary 80","author":"Joint Formulary Committee","year":"2020","unstructured":"Joint Formulary Committee. British national formulary 80. London: BMJ Publishing and the Royal Pharmaceutical Society; 2020."},{"key":"1173_CR32","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S2468-2667(20)30287-5","volume":"6","author":"RE Watkinson","year":"2021","unstructured":"Watkinson RE, Sutton M, Turner AJ. Ethnic inequalities in health-related quality of life among older adults in England: secondary analysis of a national cross-sectional survey. Lancet Public Health. 2021;6:e145\u201354.","journal-title":"Lancet Public Health."},{"key":"1173_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jchf.2013.12.003","volume":"2","author":"EF Lewis","year":"2014","unstructured":"Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Fail. 2014;2:159\u201365.","journal-title":"JACC Heart Fail."},{"key":"1173_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: Technology appraisal guidance [TA394]. 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta394\/resources\/evolocumab-for-treating-primary-hypercholesterolaemia-and-mixed-dyslipidaemia-82602910172869. Accessed 5 Jul 2022."},{"key":"1173_CR35","unstructured":"National Institute for Health and Care Excellence (NICE). Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: Technology appraisal guidance [TA393]. 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta393\/resources\/alirocumab-for-treating-primary-hypercholesterolaemia-and-mixed-dyslipidaemia-82602908493253. Accessed 5 Jul 2022."},{"key":"1173_CR36","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","volume":"75","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, et al. Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020;75:2297\u2013308.","journal-title":"J Am Coll Cardiol"},{"key":"1173_CR37","doi-asserted-by":"crossref","unstructured":"Bagepally BS, Sasidharan A. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. Eur J Clin Pharmacol. 2021;78(3):351\u2013363.","DOI":"10.1007\/s00228-021-03242-6"},{"key":"1173_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40273-018-0671-0","volume":"36","author":"MJ Korman","year":"2018","unstructured":"Korman MJ, Retterst\u00f8l K, Kristiansen IS, Wisl\u00f8ff T. Are PCSK9 inhibitors cost effective? Pharmacoeconomics. 2018;36:1031\u201341.","journal-title":"Pharmacoeconomics"},{"key":"1173_CR39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10741-019-09874-2","volume":"25","author":"S Azari","year":"2020","unstructured":"Azari S, Rezapour A, Omidi N, Alipour V, Behzadifar M, Safari H, et al. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review. Heart Fail Rev. 2020;25:1077\u201388.","journal-title":"Heart Fail Rev"},{"key":"1173_CR40","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090\u20138.","journal-title":"Lancet"},{"key":"1173_CR41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10557-021-07212-z","volume":"35","author":"P Sarajlic","year":"2021","unstructured":"Sarajlic P, Artiach G, Larsson SC, B\u00e4ck M. Dose-dependent risk reduction for myocardial infarction with eicosapentaenoic acid: a meta-analysis and meta-regression including the STRENGTH Trial. Cardiovasc Drugs Ther. 2021;35:1079\u201381.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1173_CR42","first-page":"1076","volume":"82","author":"S Kodera","year":"2018","unstructured":"Kodera S, Morita H, Kiyosue A, Ando J, Komuro I. Cost-effectiveness of statin plus eicosapentaenoic acid combination therapy for cardiovascular disease prevention in japanese patients with hypercholesterolemia\u2014an analysis based on the Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS). Circ J Off J Jpn Circ Soc. 2018;82:1076\u201382.","journal-title":"Circ J Off J Jpn Circ Soc."},{"key":"1173_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMe1814004","volume":"380","author":"JJP Kastelein","year":"2019","unstructured":"Kastelein JJP, Stroes ESG. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380:89\u201390.","journal-title":"N Engl J Med"},{"key":"1173_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013255","volume":"7","author":"DL Steen","year":"2017","unstructured":"Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open. 2017;7: e013255.","journal-title":"BMJ Open"},{"key":"1173_CR45","first-page":"CD012502","volume":"11","author":"S Zhan","year":"2018","unstructured":"Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11:CD012502.","journal-title":"Cochrane Database Syst Rev"},{"key":"1173_CR46","first-page":"C011748","volume":"10","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Carter J-PL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;10:C011748.","journal-title":"Cochrane Database Syst Rev"},{"key":"1173_CR47","doi-asserted-by":"publisher","unstructured":"Michaeli DT, Mills M, Michaeli T, Miracolo A, Kanavos P. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Invest New Drugs. 2022. https:\/\/doi.org\/10.1007\/s10637-022-01227-5.","DOI":"10.1007\/s10637-022-01227-5"},{"key":"1173_CR48","doi-asserted-by":"publisher","unstructured":"Michaeli DT, Mills M, Kanavos P. Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ Health Policy. 2022. https:\/\/doi.org\/10.1007\/s40258-022-00737-w.","DOI":"10.1007\/s40258-022-00737-w"},{"key":"1173_CR49","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743\u201353.","journal-title":"JAMA"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01173-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01173-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01173-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:50:59Z","timestamp":1659106259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01173-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01173-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"16 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DM served as an advisor to NB Capital ApS. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Concept and design: DM, TM. Acquisition of data: DM, TM. Analysis and interpretation of data: DM, JM, TB, TM. Drafting of the manuscript: DM. Critical revision of the paper for important intellectual content: DM, JM, TB, TM. Statistical analysis: DM. Supervision: DM, JM, TB, TM.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data underlying this study are available in the article and in its online supplementary material.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}